Spectral AI showcased its DeepView System at the 2026 British Burn Association Annual Conference, where Dr. Jeffrey Carter won first prize for his presentation on using multispectral imaging combined with AI to assess burn wounds. The DeepView System, which received FDA De Novo classification in May 2026 and UKCA authorization in 2024, provides rapid, data-driven assessments to aid treatment decisions for burn patients. The technology is gaining recognition for improving burn care globally by enabling faster, more accurate diagnostics and treatment planning. Spectral AI continues to lead innovation in wound care diagnostics with its AI-powered device.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
Several stocks experienced significant declines today driven by company-specific events. SANUWAVE Health's shares dropped 39.21% despite strong revenue guidance, Twin Vee Powercats fell 30.95% amid a legal investigation, and Gorilla Technology declin...
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
